N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Active, not recruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 2/Phase 3
2008-08-01
This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu®) will
enhance the ability of the liver to dispose of toxic ammonia which accumulates in several
metabolic diseases including urea cycle disorders and organic acid disorders.
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Active, not recruiting
Mendel Tuchman
Phase 2/Phase 3
2008-08-01
This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu®) will
enhance the ability of the liver to dispose of toxic ammonia which accumulates in several
metabolic diseases including urea cycle disorders and organic acid disorders.
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate
Withdrawn
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 2
2010-12-01
Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors
of metabolism. The investigators propose to determine if short-term (3 day) treatment with
N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients.
The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators
would consider more extensive long-term studies of the drug.
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate
Withdrawn
Children's Hospital of Philadelphia
Phase 2
2010-12-01
Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors
of metabolism. The investigators propose to determine if short-term (3 day) treatment with
N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients.
The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators
would consider more extensive long-term studies of the drug.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
